Caseware UK (AP4) 2023.0.135 2023.0.135 2024-03-312024-03-31truetruetruetruetruefalse2023-04-01Wholesale Pharmaceuical2528truetruefalse 07286885 2023-04-01 2024-03-31 07286885 2022-04-01 2023-03-31 07286885 2024-03-31 07286885 2023-03-31 07286885 c:Director1 2023-04-01 2024-03-31 07286885 d:CurrentFinancialInstruments 2024-03-31 07286885 d:CurrentFinancialInstruments 2023-03-31 07286885 d:CurrentFinancialInstruments d:WithinOneYear 2024-03-31 07286885 d:CurrentFinancialInstruments d:WithinOneYear 2023-03-31 07286885 d:ShareCapital 2024-03-31 07286885 d:ShareCapital 2023-03-31 07286885 d:RetainedEarningsAccumulatedLosses 2024-03-31 07286885 d:RetainedEarningsAccumulatedLosses 2023-03-31 07286885 c:FRS102 2023-04-01 2024-03-31 07286885 c:Audited 2023-04-01 2024-03-31 07286885 c:FullAccounts 2023-04-01 2024-03-31 07286885 c:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 07286885 c:SmallCompaniesRegimeForAccounts 2023-04-01 2024-03-31 07286885 e:PoundSterling 2023-04-01 2024-03-31 iso4217:GBP xbrli:pure

Registered number: 07286885









PHARMADENT LIMITED









FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 MARCH 2024

 
PHARMADENT LIMITED
REGISTERED NUMBER: 07286885

BALANCE SHEET
AS AT 31 MARCH 2024

2024
2023
Note
£
£

  

Current assets
  

Stocks
  
-
206,137

Debtors: amounts falling due within one year
 4 
2,091,399
1,692,401

Cash at bank and in hand
 5 
3,817
160

  
2,095,216
1,898,698

Creditors: amounts falling due within one year
 6 
(957,828)
(771,577)

Net current assets
  
 
 
1,137,388
 
 
1,127,121

Total assets less current liabilities
  
1,137,388
1,127,121

  

Net assets
  
1,137,388
1,127,121


Capital and reserves
  

Called up share capital 
  
1
1

Profit and loss account
  
1,137,387
1,127,120

  
1,137,388
1,127,121


The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 23 December 2024.




B Patel
Director

The notes on pages 2 to 6 form part of these financial statements.
Page 1

 
PHARMADENT LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

1.


General information

Pharmadent Limited is a private company, limited by shares, domiciled in England and Wales, registration number 07286885. The registered office is Haslers, Old Station Road, Loughton, Essex, IG10 4PL. The principal activity of the company continued to be that of wholesalers of pharmaceutical goods.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Financial Reporting Standard 102 - reduced disclosure exemptions

The Company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by the FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":
the requirements of Section 7 Statement of Cash Flows;
the requirements of Section 3 Financial Statement Presentation paragraph 3.17(d);
the requirements of Section 11 Financial Instruments paragraphs 11.42, 11.44 to 11.45, 11.47, 11.48(a)(iii), 11.48(a)(iv), 11.48(b) and 11.48(c);
the requirements of Section 12 Other Financial Instruments paragraphs 12.26 to 12.27, 12.29(a), 12.29(b) and 12.29A;
the requirements of Section 33 Related Party Disclosures paragraph 33.7.

This information is included in the consolidated financial statements of Pharmadent Holdings Limited as at 31 March 2024 and these financial statements may be obtained from Companies House.

Page 2

 
PHARMADENT LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

2.Accounting policies (continued)

 
2.3

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of Comprehensive Income within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

 
2.4

Revenue

Revenue from the sale of the pharmaceutical products is recognised at a fair value, when the stock leaves the companies warehouse, excluding discouujnts, rebates, value added tax and other sales taxes. At this point the Company considers that the significant risks and rewards of ownership have been transferred to the buyer.

 
2.5

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.6

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

 
2.7

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Page 3

 
PHARMADENT LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

2.Accounting policies (continued)

 
2.8

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a weighted average basis.
At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.9

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.10

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.11

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Employees

The average monthly number of employees, including directors, during the year was 25 (2023 - 28).


4.


Debtors

2024
2023
£
£


Trade debtors
6,081
-

Amounts owed by group undertakings
2,085,318
1,235,761

Other debtors
-
456,640

2,091,399
1,692,401


Page 4

 
PHARMADENT LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

5.


Cash and cash equivalents

2024
2023
£
£

Cash at bank and in hand
3,817
160

Less: bank overdrafts
(82)
(115,414)

3,735
(115,254)



6.


Creditors: Amounts falling due within one year

2024
2023
£
£

Bank overdrafts
82
115,414

Trade creditors
802,120
357,623

Corporation tax
2,174
43,244

Other taxation and social security
21,804
20,661

Other creditors
121,531
82,802

Accruals and deferred income
10,117
151,833

957,828
771,577



7.


Related party transactions

At the year end the following amounts were due from/(to) the related parties:


2024
2023
£
£

Entities under common control
-
256,780
-
256,780


8.


Controlling party

The ultimate parent company is Pharmadent Holdings Limited, a company registered in England and Wales.
The ultimate controlling party is B Patel, by virtue of his significant shareholding in the ultimate parent company.
Page 5

 
PHARMADENT LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

9.


Auditors' information

The auditors' report on the financial statements for the year ended 31 March 2024 was unqualified.

The audit report was signed on 23 December 2024 by Matthew Wells ACA (Senior Statutory Auditor) on behalf of Haslers.

 
Page 6